piracetam has been researched along with Depressive Disorder, Major in 5 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to identify clinical correlates of self-reported aggressiveness (SRA) in patients with epilepsy treated with levetiracetam (LEV) with special reference to the role of depression." | 3.81 | Self-reported aggressiveness during treatment with levetiracetam correlates with depression. ( Agrawal, N; Cock, HR; Lozsadi, DA; Mohanalingham, K; Mula, M; Mustafa, Z; von Oertzen, TJ, 2015) |
| "Lance-Adams syndrome is usually recognized only in a late phase, preventing the early rehabilitation." | 1.31 | [Treatment and long-term follow-up of post-anoxic myoclonus]. ( Halász, P; Holló, A; Janszky, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mula, M | 1 |
| Agrawal, N | 1 |
| Mustafa, Z | 1 |
| Mohanalingham, K | 1 |
| Cock, HR | 1 |
| Lozsadi, DA | 1 |
| von Oertzen, TJ | 1 |
| Wier, LM | 1 |
| Tavares, SB | 1 |
| Tyrka, AR | 1 |
| Price, LH | 1 |
| Carpenter, LL | 1 |
| Janszky, J | 1 |
| Holló, A | 1 |
| Halász, P | 1 |
| Eckmann, F | 1 |
| Borromei, A | 1 |
| Caramelli, R | 1 |
| Conti, M | 1 |
| Giancola, LC | 1 |
| Guerra, L | 1 |
1 trial available for piracetam and Depressive Disorder, Major
| Article | Year |
|---|---|
[Clinical studies with piracetam].
Topics: Age Factors; Clinical Trials as Topic; Depression; Depressive Disorder, Major; Female; Humans; Male; | 1976 |
4 other studies available for piracetam and Depressive Disorder, Major
| Article | Year |
|---|---|
Self-reported aggressiveness during treatment with levetiracetam correlates with depression.
Topics: Adult; Aggression; Anticonvulsants; Depressive Disorder, Major; Epilepsy; Female; Humans; Levetirace | 2015 |
Levetiracetam-induced depression in a healthy adult.
Topics: Adult; Anticonvulsants; Clinical Protocols; Depressive Disorder, Major; Dose-Response Relationship, | 2006 |
[Treatment and long-term follow-up of post-anoxic myoclonus].
Topics: Adult; Cognition Disorders; Depressive Disorder, Major; Female; Humans; Hypoxia, Brain; Myoclonus; N | 2001 |
[Nonpsychotic involutional inhibited depressions and psycho-organic deteriorations: treatment with Viloxazine and piracetam].
Topics: Administration, Oral; Aged; Depressive Disorder, Major; Drug Evaluation; Female; Humans; Male; Middl | 1989 |